3 completed, 2 terminated, 1 recruiting. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Terminated 2, Recruiting 1 |
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Quality-of-Life Assessment, Radiation Therapy, Talazoparib - Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-26 | 2026-03-11 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 16 | 2018-06-01 | 2025-05-31 |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Adavosertib, Cisplatin, External Beam Radiation Therapy - Cervical Carcinoma, Endometrioid Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 10 | 2018-05-29 | 2024-02-20 |
| Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Cisplatin, Laboratory Biomarker Analysis, Paclitaxel - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2011-03-14 | 2019-07-18 |
Uterine Cervical Neoplasms (6) · Vaginal Neoplasms (4) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Vulvar Neoplasms (2) · Carcinoma, Endometrioid (1) · Peritoneal Neoplasms (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Uterine Cervical Diseases (6) · Uterine Diseases (6) · Uterine Neoplasms (6) · Adnexal Diseases (4) · Endocrine System Diseases (4) · Gonadal Disorders (4)
1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Platinum (2) · Radiation (2) · Radiotherapy (2) · durvalumab (2) · tremelimumab (2) · CTLA-4 Antigen (1) · Congresses as Topic (1) · Disulfides (1) · Immunoglobulin G (1) · Ipilimumab (1) · Nivolumab (1) · Paclitaxel (1) · Pharmacogenomic Variants (1)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2) · Dana-Farber Cancer Institute (1)
United States (6) · Canada (1)
Lilie L Lin (2) · Amir A Jazaeri (1) · Martin King, MD, PhD (1) · Ritu Salani (1) · Stephanie Lheureux (1)
PMID 27998970, PMID 38471508, PMID 40273550
U10CA027469 (1), UM1CA186644 (1)